ILP-2 modeling and virtual screening of an FDA-approved library:a possible anticancer therapy | Zendy

Saeed Khalili | Zendy; Hemn Mohammadpour | Zendy; Mahdieh Shokrollahi Barough | Zendy; Parviz Kokhaei | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

ILP-2 modeling and virtual screening of an FDA-approved library:a possible anticancer therapy

Author(s) -

Saeed Khalili,

Hemn Mohammadpour,

Mahdieh Shokrollahi Barough,

Parviz Kokhaei

Publication year - 2016

Publication title -

turkish journal of medical sciences

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.277

H-Index - 27

eISSN - 1303-6165

pISSN - 1300-0144

DOI - 10.3906/sag-1503-2

Subject(s) - medicine , virtual screening , pharmacology , medical physics , bioinformatics , drug discovery , biology

The members of the inhibitors of apoptosis protein (IAP) family inhibit diverse components of the caspase signaling pathway, notably caspase 3, 7, and 9. ILP-2 (BIRC-8) is the most recently identified member of the IAPs, mainly interacting with caspase 9. This interaction would eventually lead to death resistance in the case of cancerous cells. Therefore, structural modeling of ILP-2 and finding applicable inhibitors of its interaction with caspase 9 are a compelling challenge.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research